AFT Pharma Reports Record Earnings, Boosted Sales and Significant Launches in US
New Zealand-based AFT Pharmaceuticals Ltd (ASX:AFP) has reported a rise of 46 percent in net profit for the twelve months ended March 31, in addition to significant rises in operating revenue, product sales and in particular sales in overseas markets, which rose by 70 percent.
AFT Pharmaceuticals' Net Profit Climbs 46% in Fiscal 2024; Dividend Declared
AFT Pharmaceuticals (ASX:AFP, NZE:AFT) reported a net profit after tax of NZ$15.6 million for the 12 months ended March, a 46% surge on the year-ago period, according to a Thursday filing with the New
AFT Pharmaceuticals Ltd: APP 2
AFT Pharmaceuticals Ltd: FY2024 Annual Report
AFT Pharmaceuticals Ltd: AFT reports record revenue and earnings - presentation
AFT Pharmaceuticals Ltd: AFT reports record revenue and earnings
AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV
AFT Pharmaceuticals (NZE:AFT, ASX:AFP) signed a licensing agreement with Brazilian hospital injectables manufacturer Halex Istar for its proprietary pain relief medicine Maxigesic IV, according to a W
New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment
New Zealand shares rose on Wednesday's close, following a US rally caused by better-than-expected earnings reports from megacap companies. The S&P/NZX 50 Index jumped 1.21% or 143.15 points to close a
AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment
AFT Pharmaceuticals (NZE:AFT, ASX:AFP) teamed up with Massey University's commercialization arm, Massey Ventures, and charitable foundation Gillies McIndoe Research Institute to develop a topical trea
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down
New Zealand shares were flat on Monday's close as investors mostly kept to the sidelines to weigh in on the most recent trade release. The S&P/NZ50 Index changed little to close at 11,724.21. Stats NZ
AFT Pharmaceuticals to Expand Global Footprint With Signing of Supply, Production Deals
AFT Pharmaceuticals (NZE:AFT) is set to expand its global footprint following the signing of supply agreements and production deals, the pharmaceutical firm said on Monday. The pharma company signed a
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance
New Zealand shares rebounded on Friday's close as the January manufacturing activity read provided a glimmer of hope for an eventual recovery. The S&P/NZ50 Index rose 0.73% or 84.44 points to close at
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024
AFT Pharmaceuticals (NZE:AFT, ASX:AFP) expects to log an operating profit of NZ$23 million to NZ$25 million in the fiscal year ending March 31, the pharmaceutical firm said on Friday. The guidance was
AFT Pharmaceuticals Ltd.: Now Expect FY24 Operating Profit Between NZ$23M and NZ$25M
AFT Pharmaceuticals Ltd.: Now Expect FY24 Operating Profit Between NZ$23M and NZ$25M
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%
AFT Pharmaceuticals (NZE:AFT, ASX:AFP), via its licensee Hikma Pharmaceuticals, launched the intravenous pain relief medication Maxigesic IV in the US under the brand name Combogesic IV. Commercial sa
AFT Pharmaceuticals' Maxigesic IV Launches in the US
AFT Pharmaceuticals (ASX:AFP, NZX:AFT) said Maxigesic IV has been launched in the US by its licensee Hikma Pharmaceuticals, under the brand Combogesic IV. The first commercial sale of the medicine in
AFT Pharmaceuticals Ties Up With Belgian Firm to Develop Skin Medication
AFT Pharmaceuticals (NZE:AFT, ASX:AFP) joined forces with Belgian partner Hyloris Pharmaceuticals to develop the HY-091 medication intended for patients with the skin condition vulvar lichen sclerosus
AFT Pharmaceuticals Ties Up With Hyloris to Develop Burning Mouth Syndrome Treatment Candidate
AFT Pharmaceuticals (NZE:AFT, ASX:AFP) teamed up with Belgian firm Hyloris Pharmaceuticals to develop the product candidate HY-090, intended as a treatment for burning mouth syndrome. According to the
AFT Pharmaceuticals Secures Clearance to Sell Antiseptic Ointment in China
AFT Pharmaceuticals (NZE:AFT, ASX:AFP) secured regulatory clearance to market and sell its Crystalderm antiseptic ointment product in China. The pharmaceutical firm plans to launch the product in the
AFT Pharmaceuticals Secures US FDA Approval for Sale of Intravenous Pain Relief Drug
The US FDA approved Maxigesic IV, an intravenous form of AFT Pharmaceuticals' (ASX:AFP, NZE:AFT) patented pain relief medicine, for sale in the US, the pharmaceutical company said Wednesday. The medic
No Data